The estimated Net Worth of Robert W Pangia is at least $6.81 Milion dollars as of 18 March 2019. Mr. Pangia owns over 6,114 units of Biogen Inc stock worth over $4,917,722 and over the last 21 years he sold BIIB stock worth over $1,399,657. In addition, he makes $497,095 as Independent Director at Biogen Inc.
Robert has made over 16 trades of the Biogen Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 6,114 units of BIIB stock worth $319,273 on 18 March 2019.
The largest trade he's ever made was exercising 30,000 units of Biogen Inc stock on 5 May 2004 worth over $191,400. On average, Robert trades about 3,111 units every 129 days since 2004. As of 18 March 2019 he still owns at least 24,701 units of Biogen Inc stock.
You can see the complete history of Mr. Pangia stock trades at the bottom of the page.
Robert W. Pangia is an Independent Director of Biogen Inc. Mr. Pangia served as a director of the Company from 1997 to 2003 during the period the Company was operated as IDEC Pharmaceuticals, and has served as a director since 2003 following IDEC’s merger with Biogen, Inc. Mr. Pangia has been a partner in Ivy Capital Partners, LLC, the general partner of Ivy Healthcare Capital, L.P., a private equity fund specializing in healthcare investments, since 2003. From 2011 to 2016 he was also the Chief Executive Officer of Ivy Sports Medicine, LLC, a medical device company. From October 2007 to October 2009 he also served as the Chief Executive Officer of Highlands Acquisition Corp., a special purpose acquisition company. From 1996 to 2003 Mr. Pangia was self-employed as an investment banker. From 1987 to 1996 he held various senior management positions at PaineWebber, a financial services company, including Executive Vice President and Director of Investment Banking for PaineWebber Incorporated of New York, a member of the Board of Directors of PaineWebber, Inc., Chairman of PaineWebber Properties, Inc. and a member of several of PaineWebber’s executive and operating committees.
As the Independent Director of Biogen Inc, the total compensation of Robert Pangia at Biogen Inc is $497,095. There are 10 executives at Biogen Inc getting paid more, with Michel Vounatsos having the highest compensation of $18,159,900.
Robert Pangia is 67, he's been the Independent Director of Biogen Inc since 1997. There are 3 older and 21 younger executives at Biogen Inc. The oldest executive at Biogen Inc is Stelios Papadopoulos, 72, who is the Independent Chairman of the Board.
Robert's mailing address filed with the SEC is BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE, MA, 02142.
Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner a Stelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.
through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
Biogen Inc executives and other stock owners filed with the SEC include: